Peptides for Gut Health
Types, Benefits & Clinical Applications 2026
Gut health peptides are short amino acid chains that deliver targeted signals to your intestinal cells — telling them to seal a leaky barrier, heal damaged tissue, or calm an overactive immune response. The three main compounds studied for this purpose are Larazotide (barrier repair), Body Protection Compound-157 or BPC-157 (tissue healing), and KPV (inflammation control). Clinical evidence ranges from Phase 3 trials for Larazotide to primarily animal data for BPC-157 and KPV, and the regulatory situation for two of the three is actively in flux.
Key takeaways
- Gut health peptides fall into three categories: barrier-strengthening (Larazotide), tissue-repair (BPC-157), and anti-inflammatory (KPV). The right one depends on what’s actually broken in your gut.
- Larazotide has the strongest clinical evidence — a Phase 2b trial (n=342) showed symptom improvement in nonresponsive celiac disease at the 0.5 mg dose, and Phase 3 trials are underway.
- KPV inhibits the NF-kB inflammatory pathway at nanomolar concentrations; preclinical colitis studies show reduced TNF-alpha, IL-1beta, and IL-6 (Dalmasso et al., Gastroenterology, 2008).
- BPC-157 is FDA Category 2 as of March 2026, meaning compounding pharmacies cannot legally prepare it. HHS announced potential reclassification in February 2026, but no formal FDA rulemaking has been published.
- Diagnostic stool testing (GI-MAP or equivalent) should guide peptide selection. High zonulin → Larazotide. High calprotectin → KPV. Tissue damage markers → BPC-157.
Before you start All peptide protocols require a physician evaluation and baseline diagnostic testing. The peptides discussed in this guide include both an investigational drug (Larazotide) and compounds currently restricted from compounding (BPC-157, KPV) — access and legality differ significantly between them.
What are gut health peptides?
Your gut lining is one of the hardest-working surfaces in your body. It renews itself completely every 3–5 days — but chronic stress, poor diet, infections, and autoimmune conditions can overwhelm that natural repair process. When damage outpaces healing, you get a breakdown in one of three ways: the barrier loosens (leaky gut), tissue erodes (ulcers, lesions), or the immune system stays chronically activated (IBD, IBS).
Gut health peptides are short amino acid chains — typically 2–15 amino acids — that signal intestinal cells to address each of these problems directly. Unlike full proteins that get broken down during digestion, these smaller molecules can reach the gut lining intact and trigger specific repair responses.
PeptideRx rates the evidence for Larazotide as Grade B (limited human trials with strong mechanism), and BPC-157 and KPV as Grade C (primarily animal data with mechanistic support).
How do gut health peptides work?
Gut peptides operate through three distinct mechanisms — and understanding which one applies to you is the key to choosing the right compound.
Barrier strengthening targets the tight junctions (the protein seals between intestinal cells). When these loosen, undigested food particles, bacteria, and toxins leak into the bloodstream and trigger system-wide immune reactions. Larazotide works here.
Tissue repair addresses physical damage to the gut lining: ulcers, erosions, and lesions from chronic inflammation or injury. BPC-157 stimulates new blood vessel growth, cell migration, and collagen deposition to rebuild damaged tissue.
Immune modulation dials down the inflammatory signaling cascades that keep the intestinal immune system in a state of chronic activation. KPV does this by inhibiting NF-kB (a master switch for inflammation) at nanomolar concentrations — without shutting down immune function broadly.
Important: Therapeutic gut peptides (Larazotide, BPC-157, KPV) are a distinct category from the peptide hormones your gut naturally produces (motilin, ghrelin, secretin). Gut hormone pathways regulate digestion and motility. These three compounds target structural repair and inflammation — different problems, different mechanisms.
Three types of gut health peptides
Key takeaways for this section
- Larazotide is a synthetic 8-amino acid peptide that blocks zonulin, the protein that opens tight junctions. It acts locally in the gut lumen with minimal systemic absorption.
- BPC-157 is a 15-amino acid peptide derived from human gastric juice. Its stability in gastric acid makes oral delivery viable — an unusual property for a therapeutic peptide.
- KPV preferentially accumulates in inflamed intestinal cells because the PepT1 transporter (its uptake mechanism) is upregulated in inflamed tissue.
Type 1: Barrier-strengthening peptides
Larazotide acetate (also known as AT-1001 or INN-202) is the primary example in this category. It’s a synthetic octapeptide (8 amino acids) originally developed as a zonulin antagonist.
Zonulin is a protein your body produces to open tight junctions — useful in normal physiology, problematic when chronically elevated. Larazotide blocks zonulin’s action and promotes redistribution of tight junction proteins (ZO-1, occludin, claudins) to keep the barrier sealed. Multiple clinical trials have confirmed both its safety and its ability to reduce GI symptoms in celiac disease (Slifer et al., American Journal of Physiology-GI and Liver Physiology, 2021).
Type 2: Tissue-repair peptides
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found in human gastric juice. It has been studied in more than 50 preclinical models for its tissue-healing effects.
BPC-157 stimulates vascular endothelial growth factor (VEGF — the signal for new blood vessel formation), promotes fibroblast migration to wound sites, and increases collagen deposition. Its stability in gastric acid is notable: most peptides break down in the stomach, but BPC-157 survives intact — which means oral administration can deliver it directly to GI tissues.
Type 3: Anti-inflammatory peptides
KPV (Lysine-Proline-Valine) is a tripeptide derived from alpha-melanocyte stimulating hormone (alpha-MSH). It retains alpha-MSH’s anti-inflammatory properties without the pigmentation effects of the full hormone.
KPV inhibits NF-kB activation at nanomolar concentrations and reduces key pro-inflammatory cytokines: TNF-alpha, IL-1beta, IL-6, and IFN-gamma. Oral KPV reduced colitis severity in both DSS-induced and TNBS-induced mouse models, decreasing inflammatory cytokine expression and preserving colonic tissue (Dalmasso et al., Gastroenterology, 2008; PMID: 18061177).
An advanced nanoparticle delivery system (HA-KPV-NPs) showed equivalent effects at concentrations 12,000-fold lower than free KPV in preclinical models (Xiao et al., Molecular Therapy, 2017; PMC5498804) — though this formulation is not standard in current clinical use.
Diagnostic testing: matching peptides to your gut dysfunction
Symptoms like bloating, irregular bowel movements, and food sensitivities don’t point to a single cause. They could result from barrier dysfunction, chronic inflammation, microbial imbalance (dysbiosis), or a combination. Diagnostic testing gives you the data to match the right peptide to the right problem — and to avoid taking something that doesn’t address what’s actually wrong.
GI-MAP and comprehensive stool analysis
GI-MAP (Gastrointestinal Microbial Assay Plus) is a DNA-based stool test that measures gut health biomarkers directly. Other comprehensive stool panels provide comparable data. The markers most relevant to peptide selection:
- Zonulin: Elevated levels signal tight junction dysfunction — the direct target of Larazotide. (Note: Current ELISA kits for zonulin have measurement accuracy limitations flagged in recent literature; discuss interpretation with your physician.)
- Calprotectin and lactoferrin: High levels indicate active intestinal inflammation — KPV’s primary target.
- Pathogenic markers: Bacteria, parasites, and viruses that need direct treatment before or alongside any peptide protocol.
- Dysbiosis indicators: Microbial imbalance that guides probiotic pairing.
From test result to peptide selection
| GI-MAP finding | What it means | Peptide recommendation |
|---|---|---|
| Elevated zonulin | Tight junctions loosening; intestinal barrier compromised | Larazotide (barrier strengthening) |
| High calprotectin or lactoferrin | Active intestinal inflammation | KPV (anti-inflammatory) |
| Tissue damage indicators | Gut lining erosion or ulceration | BPC-157 (tissue repair) |
| Multiple elevated markers | Combined barrier + inflammation + tissue damage | Combination protocol under physician supervision |
| Dysbiosis, no barrier dysfunction | Microbial imbalance without structural damage | Probiotics and dietary intervention first; peptides may not be indicated |
Important: A patient with high zonulin but normal inflammation markers needs barrier support — not an anti-inflammatory. A patient with high calprotectin but normal zonulin needs immune modulation — not barrier tightening. Testing first prevents the common mistake of treating the wrong problem.
Best peptides for gut health: evidence by compound
| Peptide | Mechanism | Target condition | Evidence level | Delivery | Regulatory status |
|---|---|---|---|---|---|
| Larazotide | Zonulin antagonist; tightens tight junctions | Leaky gut, celiac disease | Phase 2/3 clinical trials | Oral (0.5–1 mg, 3x daily in trials) | FDA investigational drug |
| BPC-157 | Angiogenesis, fibroblast migration, collagen synthesis | Gut ulcers, erosions, gastritis | 50+ preclinical studies; limited human data | Oral capsule or subcutaneous injection (250–500 mcg) | FDA Category 2 (compounding restricted) |
| KPV | NF-kB pathway inhibition; reduces TNF-alpha, IL-1beta, IL-6 | IBD, IBS, autoimmune gut inflammation | Moderate preclinical (colitis models) | Oral, sublingual, or subcutaneous | FDA Category 2 (compounding restricted) |
| BPC-157 + KPV | Dual: tissue repair + inflammation control | Complex presentations with both tissue damage and active inflammation | Preclinical for individual compounds; combination rationale is mechanistic | Oral or compounded formulation | Category 2 restrictions apply to both |
Larazotide: the barrier specialist
Key takeaways
- The 0.5 mg dose (3x daily for 12 weeks) was the only dose that met the primary efficacy endpoint in the Phase 2b trial — the 1 mg and 2 mg doses did not show statistical significance.
- Larazotide acts locally in the gut lumen with minimal systemic absorption — which is why its side effect profile is so clean.
- Phase 3 trials for nonresponsive celiac disease are underway as of 2026.
Larazotide is the most clinically advanced gut peptide. Originally developed by Alba Therapeutics and now under 9 Meters Biopharma, it has completed multiple clinical trials for celiac disease.
The Phase 2b trial (Leffler et al., Gastroenterology, 2015; n=342 patients with nonresponsive celiac disease) compared doses of 0.5 mg, 1 mg, and 2 mg taken three times daily for 12 weeks. The 0.5 mg dose significantly improved the Celiac Disease Gastrointestinal Symptom Rating Scale score compared to placebo — fewer symptomatic days, reduced abdominal pain, and decreased headache and fatigue. Higher doses did not reach statistical significance.
A 2021 review in the American Journal of Physiology (Slifer et al.) confirmed Larazotide’s barrier-protective effects via tight junction protein redistribution and myosin light chain kinase inhibition.
The most common side effects across trials: urinary tract infection and headache — both mild, and not significantly different from placebo rates.
BPC-157: the tissue healer
Key takeaways
- Over 50 preclinical studies demonstrate BPC-157’s ability to accelerate healing of gut ulcers, surgical reconnections, and inflammatory lesions.
- BPC-157 is stable in gastric acid — an unusual property that makes oral delivery viable for GI applications.
- Access is currently restricted: BPC-157 is FDA Category 2 as of March 2026.
BPC-157 has the most extensive preclinical GI evidence of any gut-targeted peptide. Its mechanism chain in the gut:
BPC-157 → stimulates VEGF expression → increases blood flow to damaged areas → promotes fibroblast migration → collagen deposition → tissue rebuilding
No lethal or toxic dose has been identified in preclinical studies. Common reports from clinical use include mild GI adjustment in the first week (nausea, bloating) that typically resolves.
Important: BPC-157 has a theoretical angiogenesis concern — new blood vessel formation could theoretically support tumor growth. No clinical evidence confirms this risk, but it is a contraindication for patients with active malignancy.
Learn more about BPC-157’s regulatory timeline and what the February 2026 HHS announcement means.
KPV: the inflammation calmer
KPV’s anti-inflammatory mechanism is specific: it inhibits NF-kB, the transcription factor that acts as a master switch for the inflammatory cascade, at nanomolar concentrations. This precision means it reduces pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IFN-gamma) without broadly suppressing immune function.
What makes KPV’s delivery profile notable: it enters intestinal cells via the PepT1 transporter, which is upregulated in inflamed tissue. KPV preferentially accumulates where it’s most needed.
Preclinical evidence: oral KPV reduced colitis severity in DSS-induced and TNBS-induced mouse models, decreasing inflammatory cytokine expression and preserving colonic tissue architecture (Dalmasso et al., 2008). Human safety data remains limited.
BPC-157 + KPV combination protocols
Some practitioners prescribe BPC-157 and KPV together when diagnostic testing shows both tissue damage and active inflammation. The logic is direct: BPC-157 handles structural repair while KPV addresses the immune response driving ongoing damage. The mechanisms don’t overlap — they address different problems simultaneously.
Combination protocols require physician supervision. Dosing, timing, and duration should be individualized based on diagnostic findings and clinical response.
Peptides for specific gut conditions
Leaky gut (increased intestinal permeability)
Primary peptide: Larazotide
Larazotide targets the root mechanism of leaky gut — tight junction dysfunction driven by elevated zonulin. By antagonizing zonulin and promoting redistribution of ZO-1, occludin, and claudins, it addresses the structural failure directly.
Track zonulin via stool testing before and after treatment (typically 8–12 weeks in clinical trial protocols) to measure objective improvement.
IBS (irritable bowel syndrome)
Primary peptide: KPV
IBS involves low-grade intestinal inflammation and immune dysregulation that disrupts motility and visceral sensitivity. KPV’s NF-kB inhibition targets this immune component without broad immunosuppression.
One important note: IBS is a functional disorder with multiple subtypes (IBS-D, IBS-C, IBS-M). Peptide therapy addresses the inflammatory component but does not replace dietary management (low-FODMAP), stress reduction, or other evidence-based interventions.
IBD (Crohn’s disease, ulcerative colitis)
Primary peptide: KPV, or BPC-157 + KPV combination
IBD involves both chronic inflammation and tissue damage. KPV reduces the inflammatory cascade driving mucosal injury. BPC-157 addresses structural healing of damaged tissue. The combination rationale follows the biology.
Important: Peptide therapy for IBD should complement — not replace — conventional treatments including 5-ASA medications, biologics, and immunomodulators. Coordinate with your gastroenterologist before adding peptides to an existing IBD protocol.
Gastritis and peptic ulcers
Primary peptide: BPC-157
BPC-157’s tissue-healing mechanism — angiogenesis, fibroblast recruitment, collagen synthesis — directly targets ulcer repair at the site of damage. Preclinical models show accelerated gastric ulcer healing.
Rule out and treat H. pylori infection before or alongside peptide therapy. BPC-157 repairs tissue but does not eradicate bacterial infection.
SIBO (small intestinal bacterial overgrowth)
Primary peptide: None as first-line treatment
SIBO requires antimicrobial treatment (rifaximin, herbal antimicrobials) to reduce bacterial overgrowth. Once the overgrowth is addressed, Larazotide can help restore intestinal barrier integrity that was damaged by the infection and resulting inflammation. Peptides alone do not treat SIBO.
Peptide therapy vs. probiotics and L-glutamine
These are complementary interventions, not competing ones. Each targets a different layer of gut function.
| Factor | Gut health peptides | Probiotics | L-glutamine |
|---|---|---|---|
| What they do | Repair barrier, heal tissue, modulate immunity via cell signaling | Restore beneficial microbial populations | Fuel intestinal epithelial cell turnover and energy production |
| What they target | Tight junctions, tissue damage, immune pathways | Microbial ecosystem composition | Enterocyte metabolism and mucosal integrity |
| Best for | Leaky gut, ulcers, IBD/IBS with inflammatory component | Dysbiosis, antibiotic recovery, microbial diversity | General mucosal support, post-illness recovery |
| Evidence level | Larazotide: Phase 2/3; BPC-157/KPV: preclinical | Multiple RCTs for specific strains and conditions | Moderate (general support; specific conditions less established) |
| Mechanism precision | Highly specific (targets identified pathways) | Broad ecosystem support | General cellular fuel (not pathway-specific) |
| When testing guides use | Elevated zonulin, high calprotectin, tissue damage | Dysbiosis markers, low beneficial species | General support alongside other interventions |
If your stool testing shows both barrier dysfunction (high zonulin) and microbial imbalance (dysbiosis), you may benefit from peptides and probiotics together. Peptides address structural damage; probiotics repopulate the healthy microbial ecosystem. L-glutamine provides general support for the cells doing the repair work.
Dosing and administration
Important: All gut health peptide protocols require physician supervision. The ranges below describe general frameworks from clinical trials — not prescribing recommendations. Dosing is individualized based on diagnostic findings, symptom severity, and patient factors.
Delivery methods
| Route | Notes |
|---|---|
| Oral capsules | Preferred for gut-targeted delivery. BPC-157 is stable in gastric acid, making oral effective for GI applications. Larazotide is oral in all clinical trials. KPV can be formulated for oral delivery. |
| Sublingual | Faster absorption; bypasses stomach acid for peptides that are not acid-stable. |
| Subcutaneous injection | Provides systemic distribution. Used when gut peptides are part of a broader protocol or when oral delivery is not appropriate. |
Clinical protocol frameworks
| Peptide | Dose range (from trials/clinical reports) | Frequency | Typical duration |
|---|---|---|---|
| Larazotide | 0.5–1 mg | Three times daily before meals | 12 weeks (as used in published trials) |
| BPC-157 | 250–500 mcg | Twice daily | 4–8 weeks, with follow-up testing |
| KPV | 10–20 mg (oral; experimental range from clinical practice reports) | Daily | Varies by condition severity |
Treatment monitoring
Baseline comprehensive stool analysis (GI-MAP or equivalent) should be obtained before starting. Repeat stool analysis at 8–12 weeks to measure objective changes in zonulin, inflammation markers, and dysbiosis indicators. Duration decisions should be based on objective improvement in test results and clinical symptoms — not fixed timelines.
Side effects and safety
Side effects by compound
| Peptide | Documented side effects | Evidence source |
|---|---|---|
| Larazotide | Urinary tract infection, headache (both mild; not significantly different from placebo rates) | Multiple Phase 2/3 clinical trials |
| BPC-157 | Mild GI adjustment in first week (nausea, bloating), typically self-resolving | Preclinical studies; limited human reports |
| KPV | Described as non-toxic and biocompatible with intestinal cells in preclinical studies; limited human safety data | Preclinical (Dalmasso et al., 2008) |
Contraindications
- Pregnancy and breastfeeding: Insufficient safety data for all gut health peptides. Avoid during pregnancy.
- Active malignancy: BPC-157’s angiogenesis mechanism is a contraindication in patients with active cancer. No clinical evidence confirms risk, but the theoretical concern is real.
- Severe autoimmune conditions: Peptides that modulate immune function (KPV) require careful physician evaluation in patients with complex autoimmune presentations.
- Active GI infections: Treat H. pylori, parasites, and SIBO before or alongside peptide therapy — not instead of antimicrobial treatment.
Learn more about evaluating peptide therapy safety with your physician.
Legal status (2026)
| Peptide | FDA status | What it means for access |
|---|---|---|
| Larazotide | Investigational drug (Phase 3 trials underway) | Not FDA-approved. Available through clinical trials or off-label prescribing at functional medicine practices. Actively progressing through the FDA regulatory pathway. |
| BPC-157 | Category 2 bulk drug substance | Cannot be compounded by pharmacies under current FDA rules. HHS Secretary Kennedy announced potential reclassification to Category 1 in February 2026, but no formal FDA rulemaking has been published as of March 2026. |
| KPV | Category 2 bulk drug substance | Same Category 2 restrictions as BPC-157. Available as a research compound but not through regulated compounding. |
MoCRA (Modernization of Cosmetics Regulation Act, 2022) expanded FDA authority over compounded products. Compounding facilities must now register with the FDA, list their products, substantiate safety, and report adverse events. These requirements raise the bar for compounding pharmacy quality — but also restrict which compounds can be prepared at all.
If you’re accessing any compounded peptide, verify that the pharmacy is FDA-registered and compliant with USP 797 sterile compounding standards.
PeptideRx will update this section when the FDA publishes formal guidance on BPC-157 and KPV reclassification.
The bottom line
Gut health peptides work through three distinct mechanisms, and the right compound depends entirely on what’s actually broken in your gut. Larazotide targets tight junction dysfunction with the strongest clinical evidence — Phase 2b trial results and Phase 3 trials underway. BPC-157 addresses tissue repair with extensive preclinical data but limited human evidence and current compounding restrictions. KPV calms intestinal inflammation through a precise NF-kB mechanism with solid preclinical support but the same regulatory constraints.
None of these compounds is a standalone gut health solution. They work best as part of a functional medicine approach that includes diagnostic testing, dietary modification, targeted supplementation, and ongoing monitoring. If you’re considering peptide therapy for a gut condition, start with comprehensive stool testing — it tells you which mechanism to target before you choose a compound.
Frequently Asked Questions
What are gut health peptides and how are they different from probiotics?
Gut health peptides are short amino acid chains that signal intestinal cells to repair the gut barrier, heal tissue damage, or reduce inflammation — they work through cell signaling, not microbial restoration. Probiotics add beneficial bacteria to your gut ecosystem. Both have roles in gut health, but they target different problems: peptides address structural and immune dysfunction; probiotics address microbial imbalance. Stool testing can show which problem (or both) you’re dealing with.
Which gut health peptide has the strongest clinical evidence?
Larazotide has the strongest clinical evidence. The Phase 2b trial (Leffler et al., Gastroenterology, 2015; n=342) showed that the 0.5 mg dose — taken three times daily for 12 weeks — significantly improved GI symptoms in nonresponsive celiac disease. Phase 3 trials are currently underway. BPC-157 and KPV have solid preclinical evidence from animal models but limited human clinical data.
Is BPC-157 legal to use for gut health?
No — not through compounding pharmacies under current regulations. BPC-157 is FDA Category 2, which means it cannot be legally compounded as of March 2026. HHS Secretary Kennedy announced potential reclassification to Category 1 in February 2026, but no formal FDA rulemaking has been published. Over 50 preclinical studies support its gut-healing properties, but it is not FDA-approved for human use, and human safety data is limited. Consult a licensed physician about legal alternatives and current access options.
Should I use gut health peptides with probiotics, or choose one?
Both, if your testing shows both problems. Peptides repair structural damage (leaky barrier, tissue erosion) and calm inflammation. Probiotics restore healthy microbial populations. If stool testing shows only dysbiosis without barrier dysfunction, probiotics alone may be the right starting point. If testing shows high zonulin without dysbiosis, a barrier peptide may be the priority. The two approaches address different layers of gut health and often work better together than either alone.
What diagnostic testing should I get before starting gut health peptides?
A comprehensive stool analysis — GI-MAP or an equivalent panel — is the standard starting point. Key markers to review: zonulin (barrier integrity), calprotectin and lactoferrin (inflammation), pathogenic organisms (infections requiring treatment), and dysbiosis indicators (microbial balance). The results guide peptide selection and provide a baseline to measure objective improvement at follow-up (typically 8–12 weeks after starting therapy).
Are there contraindications I should know about?
Yes. Pregnancy is a contraindication for all gut health peptides — there is insufficient safety data for any of them. Active malignancy is a contraindication specifically for BPC-157 due to its angiogenesis mechanism (new blood vessel formation could theoretically support tumor growth, though no clinical evidence confirms this). Patients with severe autoimmune conditions require careful physician evaluation before taking immune-modulating peptides like KPV. Active GI infections (H. pylori, parasites, SIBO) should be treated before or alongside — not replaced by — peptide therapy.
How long before gut health peptides show results?
The Larazotide Phase 2b trial used a 12-week treatment period, and this is the most commonly referenced timeline for measurable biomarker improvement. BPC-157 protocols in clinical practice typically run 4–8 weeks, with follow-up testing. Duration decisions should be based on objective improvement in stool biomarkers and symptoms — not a fixed calendar. Your physician should guide when to continue, adjust, or stop based on test results.
Ready to find out which gut health peptide matches your situation? Consult a licensed physician with functional medicine training. Start with comprehensive stool testing to identify your specific gut dysfunction, then work with your provider to design a targeted protocol based on your results.
References
- Leffler DA, Kelly CP, Green PHR, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319.e6.
- Slifer ZM, Krishnan BR, Madan J, Blikslager AT. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol. 2021;320(6):G983-G989.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177
- Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640. PMC5498804
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Slifer ZM, Blikslager AT. Larazotide acetate protects intestinal mucosal barrier from anoxia/reoxygenation injury. Biomedicines. 2025;13(10):2483.
- FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2). FDA.gov.
- HHS Secretary Robert F. Kennedy Jr. Remarks on The Joe Rogan Experience (Episode #2461), February 27, 2026.
Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy. PeptideRx does not provide medical advice, diagnosis, or treatment. The peptides discussed in this article include an investigational drug (Larazotide) and compounds not approved for human use (BPC-157, KPV). All dosing information reflects published research protocols, not prescribing recommendations. Consult a licensed healthcare provider before making any decisions about peptide therapy. Content medically reviewed [date]. Evidence grading criteria are working definitions pending formal review.
PeptideRx content is medically reviewed by licensed physicians. Our evidence grading system (Grade A/B/C) reflects the quality and quantity of published research, not a recommendation for or against use.